HR 2869
117th Congress
House
Health
Congressional oversight
Government studies and investigations
Health care costs and insurance
Medicare
Prescription drugs
Increasing Access to Biosimilars Act of 2021
Introduced: April 28, 2021
See on congress.gov
Everywhere this bill has been
4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 29, 2021
Referred to the Subcommittee on Health.
Apr 28, 2021
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 28, 2021
Referred to the Subcommittee on Health.
Apr 28, 2021
Introduced in House
Plain-English summary
Increasing Access to Biosimilars Act of 2021
This bill requires the Centers for Medicare & Medicaid Services to establish a demonstration project to evaluate the benefits of providing additional payments to providers of biosimilars under Medicare. Specifically, under the demonstration project, participating providers receive an additional payment based on the difference between the costs to the provider of furnishing the biosimilar and the cost if the provider had furnished the underlying reference biological product instead.
What's happening now
Referred to the Subcommittee on Health.
Committees of jurisdiction
4